Pharmaceuticals

Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with...

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment fol...

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in hospitals across the United States. 

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was not superior to six months of therapy with regard...

antiplatelet therapy, pharmaceuticals, cath lab, clinical trial, ticagrelor
AstraZeneca announced that the PEGASUS-TIMI 54 study, a large-scale outcomes trial involving more than 21,000 patients, successfully met its primary...
rivaroxaban, Xarelto, safety performance, Janssen, NVAF
A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (...
CVRx, Barostim neo Legacy System, pacemaker, hypertension, FDA, HDE
The U.S. Food and Drug Administration (FDA) has granted a humanitarian device exemption for the CVRx Inc. Barostim neo Legacy System.
More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication,...
CVRx, Barostim neo Legacy System, pacemaker, hypertension, FDA, HDE
The U.S. Food and Drug Administration (FDA) has granted a humanitarian device exemption for the CVRx Inc. Barostim neo Legacy System. The
Savaysa (edoxaban) tablets from Daiichi Sankyo Co. Ltd. are an oral, once-daily selective factor Xa-inhibitor to reduce the risk of stroke...
Zontivity (vorapaxar) tablets reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood...
Atherotech Diagnostics Lab offers warfarin sensitivity, Plavix sensitivity and thrombophilia risk tests. The warfarin and Plavix...

Articles

rivaroxaban, Xarelto, safety performance, Janssen, NVAF
A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (...
More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication,...
AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab
Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with...
DAPT study
Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop...

Video Center

The silence is deafening. And since radiology associations, physician groups and vendors have yet...
2 days 3 hours ago
The America College of Cardiology has released its list of key late-breaking clinical trials at the...
1 week 2 days ago
As editor of DAIC, I keep a close watch on trends in cardiovascular technology and try to predict...
4 weeks 3 days ago
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...

Comparison Charts

Sorry there is no data available